NCT00421135已完成1 期
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- toxicities
研究概览
简要总结
The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic and /or unresectable disease state after previous standard chemotherapy
排除标准
- 未提供
研究组 & 干预措施
Single Arm
Experimental
ZIO-201
干预措施: ZIO-201 (Drug)
结局指标
主要结局
toxicities
时间窗: 6 months
次要结局
- pharmacokinetics(6 months)
研究者
相似试验
已完成
1 期
Study of ZIO-201 in Advanced SarcomaAdvanced SarcomaNCT00439686Alaunos Therapeutics53
招募中
1 期
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCNon Small Cell Lung CancerNCT05430386Jiangsu Hansoh Pharmaceutical Co., Ltd.174
终止
1 期
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)Neoplasm MetastasisNCT04521621Merck Sharp & Dohme LLC76
已完成
1 期
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).Diffuse Intrinsic Pontine Glioma (DIPG)NCT01688401Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
已完成
1 期
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6Head and Neck CancerBreast CancerLymphomaPancreatic CancerBile Duct CancerChordoma of SacrumLung CancerColon CancerSarcomaLiver CancerSquamous Cell CarcinomaNCT03058289Intensity Therapeutics, Inc.111